1. Home
  2. SPHR vs AVDL Comparison

SPHR vs AVDL Comparison

Compare SPHR & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sphere Entertainment Co.

SPHR

Sphere Entertainment Co.

HOLD

Current Price

$87.43

Market Cap

2.1B

ML Signal

HOLD

Logo Avadel Pharmaceuticals plc

AVDL

Avadel Pharmaceuticals plc

HOLD

Current Price

$21.39

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPHR
AVDL
Founded
2020
2015
Country
United States
Ireland
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
SPHR
AVDL
Price
$87.43
$21.39
Analyst Decision
Buy
Buy
Analyst Count
8
9
Target Price
$65.25
$18.38
AVG Volume (30 Days)
749.3K
2.8M
Earning Date
11-04-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,075,530,000.00
$248,517,000.00
Revenue This Year
$13.02
$65.47
Revenue Next Year
$9.65
$30.88
P/E Ratio
N/A
N/A
Revenue Growth
N/A
79.88
52 Week Low
$23.89
$6.38
52 Week High
$93.49
$23.57

Technical Indicators

Market Signals
Indicator
SPHR
AVDL
Relative Strength Index (RSI) 65.22 58.82
Support Level $80.28 $21.34
Resistance Level $93.49 $21.45
Average True Range (ATR) 2.75 0.23
MACD 0.07 -0.22
Stochastic Oscillator 53.22 11.81

Price Performance

Historical Comparison
SPHR
AVDL

About SPHR Sphere Entertainment Co.

Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Share on Social Networks: